Stuart Peacock

8.5k total citations · 2 hit papers
220 papers, 5.3k citations indexed

About

Stuart Peacock is a scholar working on Economics and Econometrics, General Health Professions and Oncology. According to data from OpenAlex, Stuart Peacock has authored 220 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Economics and Econometrics, 65 papers in General Health Professions and 63 papers in Oncology. Recurrent topics in Stuart Peacock's work include Health Systems, Economic Evaluations, Quality of Life (99 papers), Healthcare Policy and Management (41 papers) and Economic and Financial Impacts of Cancer (33 papers). Stuart Peacock is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (99 papers), Healthcare Policy and Management (41 papers) and Economic and Financial Impacts of Cancer (33 papers). Stuart Peacock collaborates with scholars based in Canada, Australia and United States. Stuart Peacock's co-authors include Craig Mitton, Jeff Richardson, Neale Smith, Angelo Iezzi, Filip Mussen, Rob Baltussen, Zoltán Kaló, Maarten J. IJzerman, John B. Watkins and Kevin Marsh and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stuart Peacock

204 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force

2016 444 citations Stuart Peacock et al. Value in Health profile →
Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force

2016 301 citations Stuart Peacock et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart Peacock Canada	38	2.4k	1.5k	1.0k	849	616	220	5.3k
Jonathan Karnon Australia	37	2.3k 0.9×	1.6k 1.1×	915 0.9×	899 1.1×	845 1.4×	288	7.1k
Esther W. de Bekker‐Grob Netherlands	39	3.8k 1.5×	1.7k 1.1×	736 0.7×	741 0.9×	845 1.4×	146	7.6k
Jeffrey S. Hoch Canada	42	1.6k 0.7×	1.5k 0.9×	959 0.9×	638 0.8×	696 1.1×	292	6.2k
Roger T. Anderson United States	45	1.5k 0.6×	2.0k 1.3×	1.6k 1.5×	1.3k 1.5×	899 1.5×	226	8.0k
Louis P. Garrison United States	41	3.1k 1.3×	1.1k 0.7×	709 0.7×	603 0.7×	924 1.5×	226	6.7k
Brett Hauber United States	35	3.1k 1.3×	1.3k 0.8×	569 0.6×	468 0.6×	648 1.1×	192	6.2k
William Lawrence United States	29	1.1k 0.5×	932 0.6×	1.1k 1.1×	669 0.8×	501 0.8×	70	3.8k
Kathryn A. Phillips United States	37	1.7k 0.7×	1.3k 0.8×	646 0.6×	476 0.6×	649 1.1×	142	5.1k
David H. Howard United States	38	1.6k 0.7×	1.7k 1.1×	885 0.9×	564 0.7×	828 1.3×	195	5.3k
Fabian Camacho United States	42	893 0.4×	1.8k 1.2×	893 0.9×	825 1.0×	982 1.6×	213	7.0k

Countries citing papers authored by Stuart Peacock

Since Specialization

Citations

This map shows the geographic impact of Stuart Peacock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Peacock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Peacock more than expected).

Fields of papers citing papers by Stuart Peacock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Peacock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Peacock. The network helps show where Stuart Peacock may publish in the future.

Co-authorship network of co-authors of Stuart Peacock

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Peacock. A scholar is included among the top collaborators of Stuart Peacock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Peacock. Stuart Peacock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Izadi‐Najafabadi, Sara, Helen McTaggart‐Cowan, Ross Halperin, et al.. (2024). The impact of the COVID-19 pandemic on health-related quality of life of cancer patients in British Columbia. Journal of Patient-Reported Outcomes. 8(1). 100–100.

Gottschlich, Anna, Quan Hong, Lovedeep Gondara, et al.. (2024). Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study. Cancer Epidemiology Biomarkers & Prevention. 33(7). 904–911. 1 indexed citations

Pataky, Reka, Stuart Peacock, Stirling Bryan, Mohsen Sadatsafavi, & Dean A. Regier. (2024). Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework. Applied Health Economics and Health Policy. 23(3). 441–452. 1 indexed citations

Ruan, Yibing, Jennifer J. Telford, Mary A. De Vera, et al.. (2023). Association of Reducing the Recommended Colorectal Cancer Screening Age With Cancer Incidence, Mortality, and Costs in Canada Using OncoSim. JAMA Oncology. 9(10). 1432–1432. 14 indexed citations

Cheung, Douglas C., Karen E. Bremner, Reka Pataky, et al.. (2023). The impact of the early COVID-19 pandemic on healthcare system resource use and costs in two provinces in Canada: An interrupted time series analysis. PLoS ONE. 18(9). e0290646–e0290646. 11 indexed citations

Sayre, Eric C., Reka Pataky, Helen McTaggart‐Cowan, et al.. (2023). Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing Study. Cancer Epidemiology Biomarkers & Prevention. 33(1). 72–79. 3 indexed citations

Gottschlich, Anna, Lovedeep Gondara, Laurie Smith, et al.. (2023). Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study. The Lancet Regional Health - Americas. 26. 100598–100598. 3 indexed citations

Bentley, Colene, et al.. (2022). Impact of cancer on income, wealth and economic outcomes of adult cancer survivors: a scoping review. BMJ Open. 12(9). e064714–e064714. 9 indexed citations

Pataky, Reka, Stirling Bryan, Mohsen Sadatsafavi, Stuart Peacock, & Dean A. Regier. (2022). Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions. PharmacoEconomics. 40(10). 931–941. 5 indexed citations

10.

Pataky, Reka, Jaclyn Beca, David Tran, et al.. (2021). Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy & Practice. 6(1). 9 indexed citations

11.

Coldman, Andrew J., Dirk van Niekerk, Mel Krajden, et al.. (2019). Disease detection at the 48‐month exit round of the HPV FOCAL cervical cancer screening trial in women per‐protocol eligible for routine screening. International Journal of Cancer. 146(7). 1810–1818. 2 indexed citations

12.

Bentley, Colene, Stuart Peacock, Julia Abelson, et al.. (2019). Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy. Health Research Policy and Systems. 17(1). 17–17. 20 indexed citations

13.

Ezeife, Doreen A., François Dionne, Aline Fusco Fares, et al.. (2019). Value assessment of oncology drugs using a weighted criterion‐based approach. Cancer. 126(7). 1530–1540. 10 indexed citations

14.

Bentley, Colene, et al.. (2019). Conducting clinical trials—costs, impacts, and the value of clinical trials networks: A scoping review. Clinical Trials. 16(2). 183–193. 51 indexed citations

15.

Bentley, Colene, et al.. (2018). Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada. BMC Health Services Research. 18(1). 339–339. 16 indexed citations

16.

Ogilvie, Gina, Dirk van Niekerk, Mel Krajden, et al.. (2018). Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. Obstetrical & Gynecological Survey. 73(11). 632–634. 32 indexed citations

17.

Mittmann, Nicole, William K. Evans, Angela Rocchi, et al.. (2012). Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. Value in Health. 15(3). 580–585. 13 indexed citations

18.

Jembere, Nathaniel, Michael A. Campitelli, Morris Sherman, et al.. (2012). Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990–2009. PLoS ONE. 7(7). e40917–e40917. 40 indexed citations

19.

Smith, Neale, Craig Mitton, Cam Donaldson, Stirling Bryan, & Stuart Peacock. (2012). Current Evaluation Practices Involving Resource Allocation Processes in Canadian Healthcare Organizations: A Survey of Senior Managers. Canadian Journal of Program Evaluation. 27(2). 1–20. 3 indexed citations

20.

Mitton, Craig, Stuart Peacock, Cam Donaldson, & Angela Bate. (2003). Using PBMA in health care priority setting: description, challenges and experience.. PubMed. 2(3). 121–7. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact